Physician profile
Stephen E Buckley
NPI 1740283126
$10,207.94
in general payments reported to CMS, 2019-2025
37 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $690 · 2021: $1,773 · 2022: $1,996 · 2023: $1,458 · 2024: $1,545 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,345.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,298.02 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,125.72 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $790.76 | 2019-2025 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $769.27 | 2019-2025 | |
| Celgene Corporation | $739.92 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $717.55 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $517.17 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $456.57 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $351.61 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $180.84 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $141.76 | 2019-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $131.83 | 2023-2025 | Dupixent |
| Allergan, INC. | $110.72 | 2019 | |
| Gilead Sciences, INC. | $101.04 | 2019-2023 | |
| Ardelyx, INC. | $81.87 | 2023-2025 | Ibsrela |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $71.69 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $68.45 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $64.33 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $49.34 | 2024-2025 | Resmetirom, Rezdiffra |
| Ferring Pharmaceuticals INC. | $48.37 | 2021-2023 | Cimzia |
| Lilly USA, LLC | $47.43 | 2025 | Omvoh |
| Evoke Pharma, INC. | $36.90 | 2020-2022 | |
| Amgen INC. | $35.42 | 2021 | |
| Genzyme Corporation | $32.25 | 2023 | |
| Aimmune Therapeutics, INC. | $31.96 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $31.21 | 2021-2025 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.09 | 2023-2024 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $23.44 | 2025 | Iqirvo |
| Ucb, INC. | $22.13 | 2019 | |
| Boston Scientific Corporation | $22.12 | 2025 | Compliance Endokit |
| Axonics, INC. | $19.57 | 2024 | Axonics |
| Novo Nordisk INC | $16.57 | 2025 | Saxenda, Wegovy |
| Mauna Kea Technologies, INC. | $14.80 | 2020 | |
| Alfasigma USA, INC. | $13.92 | 2020 | |
| Redhill Biopharma INC. | $13.30 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,605.77 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Buckley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.